Viacituro

Viacituro (BCG bacteria) is an intravesical immunotherapy used to treat bladder cancer. This immune-stimulating agent helps reduce recurrence risk after tumor removal. Suitable for patients seeking localized bladder cancer therapy. Short-term use targets superficial bladder tumors.

Viacituro is used to treat bladder cancer by stimulating the immune system to attack cancer cells in the bladder lining. It is typically administered after tumor removal to help prevent cancer recurrence. This therapy is designed for superficial bladder tumors and supports immune response against malignant cells.

Viacituro works by introducing live, weakened bacteria into the bladder, which triggers an immune reaction. Users may experience mild bladder irritation or flu-like symptoms as the body responds to the treatment. These effects are generally temporary and indicate the immune system is engaging with the therapy.

Viacituro should only be handled and administered by healthcare professionals due to its bacterial nature. Patients with active infections or compromised immune systems may not be suitable candidates. Proper storage and disposal are essential to prevent contamination or unintended exposure.

Viacituro interacts primarily with immune-modulating therapies, which may alter its effectiveness. Live vaccines should be avoided during treatment due to potential interference with immune response. Patients should inform healthcare providers about all medications, including over-the-counter and herbal products.